

# Reena Khanna

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9857491/publications.pdf>

Version: 2024-02-01

39  
papers

1,041  
citations

567144

15  
h-index

434063

31  
g-index

41  
all docs

41  
docs citations

41  
times ranked

1547  
citing authors

#	ARTICLE	IF	CITATIONS
1	Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. <i>Lancet</i> , The, 2015, 386, 1825-1834.	6.3	354
2	Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. <i>Gut</i> , 2016, 65, 1119-1125.	6.1	74
3	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1-13.	0.9	73
4	Prokinetics for Functional Dyspepsia: A Systematic Review and Meta-Analysis of Randomized Control Trials. <i>American Journal of Gastroenterology</i> , 2019, 114, 233-243.	0.2	69
5	Reproducibility of histological assessments of disease activity in UC. <i>Gut</i> , 2015, 64, 1765-1773.	6.1	66
6	Toward a Personalized Medicine Approach to the Management of Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2014, 109, 994-1004.	0.2	50
7	Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 607-618.	0.6	39
8	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1680-1713.	2.4	32
9	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, e1-e34.	0.1	32
10	Endoscopic scoring indices for evaluation of disease activity in Crohn's disease. <i>The Cochrane Library</i> , 2016, 2016, CD010642.	1.5	29
11	Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 987-997.	1.0	19
12	Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 246-255.	0.6	19
13	Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data From 5 Randomized Controlled Induction Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1121-1132.e2.	2.4	18
14	Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2139-2141.e2.	2.4	17
15	Ustekinumab for the treatment of Crohn's disease. <i>Immunotherapy</i> , 2013, 5, 803-815.	1.0	16
16	Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 727-736.e2.	2.4	16
17	A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 63-70.	3.7	15
18	Antibiotics for induction and maintenance of remission in Crohn's disease. <i>The Cochrane Library</i> , 2017, , .	1.5	10

#	ARTICLE	IF	CITATIONS
19	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 141-154.	0.1	10
20	Placebo Rates in Randomized Controlled Trials of Pouchitis Therapy. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2519-2528.	1.1	10
21	The Next Wave of Biological Agents for the Treatment of IBD. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1737-1743.	0.9	8
22	Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis. <i>The Cochrane Library</i> , 2020, 2020, CD012381.	1.5	8
23	The Evolution of Treatment Paradigms in Crohn's Disease. <i>Gastroenterology Clinics of North America</i> , 2017, 46, 661-677.	1.0	7
24	Adalimumab for maintenance of remission in Crohn's disease. <i>The Cochrane Library</i> , 2020, 2020, CD012877.	1.5	6
25	Anti-Integrins in Ulcerative Colitis and Crohn's Disease: What Is Their Place?. <i>Digestive Diseases</i> , 2016, 34, 153-159.	0.8	5
26	Evolution of the Randomized Controlled Trial in Inflammatory Bowel Disease: Current Challenges and Future Solutions. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2155-2164.	0.9	5
27	Recommendations for Standardizing Clinical Trial Design and Endoscopic Assessment in Postoperative Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1321-1331.	0.9	5
28	Cost-Effectiveness of Tight Control for Crohn's Disease With Adalimumab-Based Treatment: Economic Evaluation of the CALM Trial From a Canadian Perspective. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, 169-176.	0.1	5
29	Current and Future Status of Therapeutic Drug Monitoring in the Treatment of IBD. <i>Current Treatment Options in Gastroenterology</i> , 2014, 12, 76-89.	0.3	4
30	Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis. <i>The Cochrane Library</i> , 0, , .	1.5	4
31	Treatment of an Initial Infection with <i>Clostridium difficile</i> in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2223-2226.	0.9	3
32	Emerging Therapies for Inflammatory Bowel Diseases. <i>Digestive Diseases</i> , 2016, 34, 67-73.	0.8	3
33	Infliximab for induction of remission in Crohn's disease. <i>The Cochrane Library</i> , 0, , .	1.5	2
34	Adalimumab for maintenance of remission in Crohn's disease. <i>The Cochrane Library</i> , 0, , .	1.5	2
35	IgA-Mediated Warm Autoimmune Hemolytic Anemia as an Extraintestinal Manifestation in a Patient With Crohn Disease on Vedolizumab. <i>Inflammatory Bowel Diseases</i> , 2021, 27, e108-e109.	0.9	2
36	Challenging Question: Is Treating Inflammatory Bowel Disease an Art or Strictly an Evidence-Based Matter?. <i>Digestive Diseases</i> , 2013, 31, 213-217.	0.8	1

#	ARTICLE	IF	CITATIONS
37	Oral janus kinase inhibitors for maintenance of remission in ulcerative colitis. The Cochrane Library, 2016, , .	1.5	1
38	Prokinetics for functional dyspepsia. The Cochrane Library, 0, , .	1.5	1
39	Immunosuppression for management of Crohn's disease " Author's reply. Lancet, The, 2016, 387, 748.	6.3	0